Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food-Effect Study of Navocaftor and Galicaftor
NCT05538585Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of navocaftor and galicaftor in cystic fibrosis (CF) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration at Day 4, Time to Cmax at Day 4 and 3 more. Started Sep 2022; status: completed.
02
Drugs
navocaftorgalicaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT05538585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05538585.